Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)-MedSci.cn

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)

Yamaguchi, K; Bang, Y; Iwasa, S; Sugimoto, N; Ryu, M; Sakai, D; Chung, H; Kawakami, H; Yabusaki, H; Lee, J; Saito, K; Kawaguchi, Y; Kamio, T; Kojima, A; Sugihara, M; Shitara, K

ANNALS OF ONCOLOGY, 2020; 31 (): S235

科室
- - 订阅+
  - 更多科室
工具
服务